Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
UC Biomed Building Investment: Advancing Research at the University of Coimbra
The Universidade de Coimbra (UC) is preparing to inaugurate its new UC Biomed building in the coming months, marking a significant milestone for the institution's biomedical research and teaching capabilities. According to recent updates, the facility—located at Polo III—has entered its final pha...
Overview of the Health Innovation Award 2026: Promoting Sustainable Solutions in Healthcare
The Health Innovation Award continues its mission in 2026 by spotlighting data-driven projects that advance sustainability across Portugal’s health sector. Launched by Faculdade de Medicina da Universidade de Lisboa, Sanofi, and NTT DATA Portugal, it invites submissions through its dedicated plat...
Commitment to Health Strategies in Portugal: A Pathway Towards Sustainable Change
In advancing health strategies in Portugal, the Ordem dos Farmacêuticos met with Adalberto Campos Fernandes to urge the country to move from promising ideas to concrete implementation of the